The Latest Cardiac and Vascular News
Mr. Tommasoli formerly served as the Company’s Senior Vice President of Global Sales & Marketing since 2020 and has significant prior commercial leadership experience at Integra LifeSciences and St. Jude Medical TEL AVIV, Israel, March 20, 2023 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention […]
ANN ARBOR, Mich., March 20, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) (“Esperion” or the “Company”), today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for the issuance and sale of an aggregate of 33,170,747 shares of its common stock (or common stock equivalents in […]
CARLSBAD, Calif., March 16, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the fourth quarter and full year ended December 31, 2022. Financial statements and other information […]
Southlake, Texas, March 16, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a more valuable screening tool through the use of Artificial Intelligence (AI), today provided […]
Acquired Assets from LIVMOR, Extending Reach in Remote Monitoring and Detection with an Existing Cutting Edge FDA-Cleared Product, Halo+™ Atrial Fibrillation Detection System Partnered with Evolve Manufacturing to Build HeartBeam AIMIGo 12-Lead 3D Vector Electrocardiogram Device Received European Patent for HeartBeam AIMIGo Technology Initial FDA Submission of HeartBeam AIMIGo™, the […]
– Lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled hypertension, expected to begin in the first half of 2023 – –IPO and Nasdaq listing completed in February 2023 with total net proceeds of approximately $202.0 million, after deducting underwriting discounts, commissions and estimated offering costs – – […]
Clarified path to potential launch YUTREPIA upon resolution of litigation in late-2023 to mid-2024 Fortified financial position through 2024 Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., March 16, 2023 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today reported financial results for the […]
PHILADELPHIA, March 15, 2023 /PRNewswire/ — Clario, a leading healthcare research and technology company that generates the richest clinical evidence for the clinical trials industry, today announced Rod MacKenzie CMG, PhD. as their new Chairman of the Board of Directors. “I am excited to join the team at Clario,” said Dr. MacKenzie. “The company […]
Conference call and webcast to be held tomorrow, March 15th at 8:30 AM EST NEW YORK, March 14, 2023 /PRNewswire/ — PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid […]
Strong R&D progress & attractive commercial deals, including additional Tranexamic Acid RTU out-licensing deals Potential U.S. market approval for Maxigesic® IV in H2 2023 Promising new product candidates driving innovation and on track for a planned acceleration towards a portfolio of 30 assets before 2025 Revenues of €3 million, net […]
